Aethlon Medical Announces FDA Approval Of IDE For Oncology Indications
Aethlon Medical, Inc. (AEMD)
NASDAQ:AMEX Investor Relations:
ir.aethlonmedical.com
Company Research
Source: PR Newswire
SAN DIEGO, Oct. 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in global health, announced today that the FDA has approved its Investigational Device Exemption (IDE) application to initiate an Early Feasibility Study (EFS) of the Company's proprietary Hemopurifier® in patients with head and neck cancer in combination with standard of care pembrolizumab (Keytruda). An EFS for a medical device is similar to a phase 1 study for a drug or biologic and as such this trial will enroll a small number of patients with advanced head and neck cancer who cannot be treated with surgery or radiation. In this patient population, pembrolizumab was recently approved for initial first line treatment. Non-clinical studies conducted by Aethlon Medical's collaborators and other investigators have suggested that a primary mechanism of resistance to pembrolizumab and other immuno-oncology drugs is the secretion by tumo
Show less
Read more
Impact Snapshot
Event Time:
AEMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AEMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AEMD alerts
High impacting Aethlon Medical, Inc. news events
Weekly update
A roundup of the hottest topics
AEMD
News
- Aethlon Medical, Inc. (NASDAQ: AEMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Aethlon Medical, Inc. (NASDAQ: AEMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally [Yahoo! Finance]Yahoo! Finance
- Aethlon Medical Inc (AEMD) Q2 2025 Earnings Call Highlights: Progress in Oncology Trials and ... [Yahoo! Finance]Yahoo! Finance
- Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
AEMD
Earnings
- 11/13/24 - In-Line
AEMD
Analyst Actions
- 11/15/24 - HC Wainwright
AEMD
Sec Filings
- 11/15/24 - Form S-8
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- AEMD's page on the SEC website